ANLOTINIB ORAL . Una Opción de Tratamiento de Mantenimiento Tolerable y Potente Después de la Quimioterapia de Inducción en ES - SMALL CELL LUNG CANCER .

Efficacy And Safety Of ANLOTINIB As Maintenance Therapy After Induction Chemotherapy in Extensive - Stage Small-Cell Lung Cáncer .

The mPFS was 7.7 months (95% CI, 7.20–8.20 months) and the mOS was 11.0 months (95% CI, 9.19–12.82 months), respectively .

The most common treatment-related adverse events were hypertension (n = 9; 64.3%), fatigue (n = 6; 42.9%), followed by decreased appetite (n = 5; 35.7%), nausea (n = 5; 35.7%), weight decrease (n = 4; 28.6%), and rash (n = 4; 28.6%) .

 There were no patients who required dose reduction because of severe adverse events .

Anlotinib achieved prospective efficacy and manageable safety in the maintenance treatment of ES-SCLC .

These above outcomes demonstrated that anlotinib was a tolerable and potent maintenance treatment option after induction chemotherapy in ES-SCLC . ...